RxDoctor Payments Data

Robert West, DO

Colon & Rectal Surgery · Chesterfield, MONPI 1801051255

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 53.4% of the total. Reporting peaked in 2023 at $466 and has fallen 72.5% since, to $128 in 2025. That places this record below the midpoint for colon & rectal surgery clinicians in MO, where the typical reported total is $4,503.

$1,329in general payments, 2019–2025

Across 92 payments — averaging $14.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$709
  • Kowa Pharmaceuticals America, Inc.$172
  • Ironwood Pharmaceuticals, Inc$106
  • AbbVie$97
  • Medtronic$60
  • Trevena, Inc.$32
  • plus $153 from 6 others

What the payments were for

  • Food & beverage$1,329100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,329 in reported general payments places this provider in the 25th percentile of 36 colon & rectal surgery providers in Missouri.

See all colon & rectal surgery providers in Missouri

Medicare billing

Part B allowed, 2024
$77,488
Medicare patients
144
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide38$24,876
Hydrocortisone90$4,349
Lubiprostone13$1,967
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip61$1,384
Lidocaine-PrilocaineLidocaine/Prilocaine12$154
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$64
Amoxicillin11$21

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$97$24,87638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 36 colon & rectal surgery providers in Missouri.

Other colon & rectal surgery in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →